ARCHIVES

Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

A Special Report: Language With A Purpose–von Eschenbach’s Four Years at NCI.

May 19, 2006

NCI To Commit $10 Million For SBIR Phase II Bridge Awards.

June 20, 2008

Novartis Submits Gleevec Data To FDA Seeking Approval For Use In GI Tumors.

October 26, 2001

FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer

August 31, 2012

DCT Issues Two Pas for Small/Exploratory Grants For Clinical, Laboratory Studies

March 23, 1994

Former NCI Lab Deputy Charged With Two Criminal Counts

January 17, 1992